Skip to main content
Premium Trial:

Request an Annual Quote

Genzyme Diagnostics Forgoes Access to Future Syn-X Technologies in Effort to Resolve Dispute

NEW YORK, July 11 – Genzyme Diagnostics no longer has first offer rights to future technologies developed by Syn-X Pharma, following an agreement that resolves previous disputes between the two companies.

In a statement issued on Tuesday, Genzyme and Syn-X announced that Genzyme would continue to develop a stroke panel called NeuroTrak, while Syn-X would retain rights to future royalty payments based on product sales.

Genzyme, however, is no longer obligated to make financial obligations to Syn-X and no longer has special rights to the Canadian proteomics company’s technology.

"The new agreement is a win-win situation," Sean McNicholas, CEO of SYN-X, said in a statement. "It allows Genzyme to continue to develop the stroke technology and SYN-X the opportunity to focus on accelerating the development of our pipeline products." 

Genzyme Diagnostics said it expected to complete clinical trials of the new stroke panel in 2003.

Genzyme Diagnostics of Cambridge, Mass., is a business unit of Genzyme General. Syn-X is based in Mississauga, Ontario. It has developed the Proteomics Discovery Platform, a technology that can be used to identify drug targets as well as to develop specialized antibody-based diagnostics. 

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.